Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Anixa Biosciences, Inc.    ANIX

ANIXA BIOSCIENCES, INC.

(ANIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2020 11/24/2020 11/25/2020 11/27/2020 11/30/2020 Date
2.17(c) 2.04(c) 2.28(c) 2.78(c) 2.64 Last
206 362 268 854 342 425 324 104 270 483 Volume
-1.81% -5.99% +11.76% +21.93% -5.04% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -10,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,62x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -12,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,18x
Yield 2021 -
Capitalization 62,8 M 62,8 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 94,0%
More Financials
Company
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the... 
More about the company
All news about ANIXA BIOSCIENCES, INC.
10/27ANIXA BIOSCIENCES : to Host Conference Call to Provide Update on Programs
PR
09/16ANIXA BIOSCIENCES INC : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/08ANIXA BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
09/08ANIXA BIOSCIENCES : to Present at the 2020 H.C. Wainwright 22nd Annual Global In..
PR
08/17ANIXA BIOSCIENCES INC : Submission of Matters to a Vote of Security Holders, Ame..
AQ
08/13ANIXA BIOSCIENCES : and OntoChem Announce Identification of Additional Covid-19 ..
PR
07/28ANIXA BIOSCIENCES : Breast Cancer Vaccine Technology Nearing FDA Submission
PR
07/20ANIXA BIOSCIENCES : Announces Change to Virtual Format for 2020 Annual Meeting o..
PR
07/10ANIXA BIOSCIENCES' : CAR-T Cancer Therapy Receives Intention to Grant Notice fro..
PR
07/06ANIXA BIOSCIENCES : and OntoChem Announce Completion of Initial Screening Progra..
PR
07/02ANIXA BIOSCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-..
AQ
07/02ANIXA BIOSCIENCES : Announces Strategic Program Realignment Focused on Advanceme..
PR
06/09ANIXA BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
06/01ANIXA BIOSCIENCES : and OntoChem Have Synthesized Four Potential Covid-19 Drugs ..
PR
05/04ANIXA BIOSCIENCES : and OntoChem Announce Discovery of First Covid-19 Therapeuti..
PR
More news
News in other languages on ANIXA BIOSCIENCES, INC.

- No features available -

More news
Chart ANIXA BIOSCIENCES, INC.
Duration : Period :
Anixa Biosciences, Inc. Technical Analysis Chart | ANIX | US03528H1095 | MarketScreener
Technical analysis trends ANIXA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 8,75 $
Last Close Price 2,64 $
Spread / Highest target 241%
Spread / Average Target 231%
Spread / Lowest Target 222%
EPS Revisions
Managers
NameTitle
Amit D. Kumar Executive Chairman, President & CEO
Michael J. Catelani CFO, COO & Principal Accounting Officer
John James Monahan Independent Director
Lewis H. Titterton Lead Independent Director
Arnold M. Baskies Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANIXA BIOSCIENCES, INC.-15.24%66
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493